Pharma, R&D

J&J polishes up its new list of late-stage blockbuster candidates — and cancer remains big

J&J’s R&D group at Janssen has always kept its eyes on the blockbuster prize with a regular look at its top prospects in the pipeline. Now — after some failures and approvals — it’s offered up its latest roster of 10 top candidates for $1 billion-plus in revenue with potential approvals through the next 4 years. And there are some new drugs mixed in with some old favorites.

In a day-long business review on Wednesday, R&D chief Mathai Mammen spotlighted these 10 drugs as their most promising programs


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->